Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma
about
Hepatocellular Carcinoma: Basic and Transitional ResearchA think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis.TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progressionSorafenib in advanced hepatocellular carcinoma: current status and future perspectives.Targeting the tumor stroma in hepatocellular carcinoma.Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteinsSorafenib for the treatment of solid malignancies: what about the cancer microenvironment?Moderate swimming suppressed the growth and metastasis of the transplanted liver cancer in mice model: with reference to nervous system.Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma.Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
P2860
Q27030563-1BD2E4C5-AF47-42D1-943F-9E489B9F9391Q35131244-90D1661D-DC6E-477F-95C0-89CF417897D0Q36413746-1AEFC3CE-7EE5-4E5B-8019-DC8E2E84F3F2Q37031712-81549E17-8B2E-4E94-9578-2E08EE09C3F7Q38366586-8545A558-634E-463B-98CE-FFE9BE703B29Q42173132-A1E986C0-D14F-4EDB-BD2B-64736C5135D8Q42856089-AD0BB89E-A920-490C-A51B-CCA6DD47A14AQ42931526-266DAD44-2132-44F8-BE3D-FAEB90A50629Q53209146-4274CCF9-CB38-455D-82DD-5D5EDB8F1834Q53218066-E469944B-AE6B-4750-8A3E-40156075F2A4Q54119583-8B278119-C2E7-4EE9-B327-2033E9989890Q55692234-A26F4C5A-3C73-4C7C-88D4-00C26B0119A7Q58755253-CF659232-E74D-4BDF-9995-2204A672FE41
P2860
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Suppression of natural killer ...... ts in hepatocellular carcinoma
@ast
Suppression of natural killer ...... ts in hepatocellular carcinoma
@en
Suppression of natural killer ...... ts in hepatocellular carcinoma
@nl
type
label
Suppression of natural killer ...... ts in hepatocellular carcinoma
@ast
Suppression of natural killer ...... ts in hepatocellular carcinoma
@en
Suppression of natural killer ...... ts in hepatocellular carcinoma
@nl
prefLabel
Suppression of natural killer ...... ts in hepatocellular carcinoma
@ast
Suppression of natural killer ...... ts in hepatocellular carcinoma
@en
Suppression of natural killer ...... ts in hepatocellular carcinoma
@nl
P2093
P2860
P1433
P1476
Suppression of natural killer ...... ts in hepatocellular carcinoma
@en
P2093
Hui-Chuan Sun
Ke-Zhi Zhang
Ling-Qun Kong
Qiang-Bo Zhang
Qing-An Jia
Quan-Bao Zhang
Wei-Zhong Wu
P2860
P304
P356
10.1371/JOURNAL.PONE.0055945
P407
P577
2013-02-08T00:00:00Z